/C O R R E C T I O N -- Spinogenix/
PR Newswire —
In the news release, Spinogenix Reports Early Improvements in Phase 2 Trial of Tazbentetol in Patients with Schizophrenia at the Schizophrenia International Research Society (SIRS) 2026 Annual Congress, issued 26-Mar-2026 by Spinogenix over PR Newswire, we are advised by the company that...